

Acute ST-Segment Elevation Myocardial Infarction in a Patient with Beta Thalassemia / Hemoglobin E

Somchai Insiripong, M.D.*,
Buncha Sukananchai, M.D.**

Abstract: Acute myocardial infarction (AMI) has been very rare in beta thalassemia and has never been seen in the patients with beta-thalassemia/hemoglobin E. Herein we report a case of 38-year-old Thai man with underlying transfusion-dependent beta-thalassemia/Hb E disease which is proved by the genotype study. Other concurrent morbidities are the low LDL, low HDL, secondary hemosiderosis and hypogonadism. He presents with acute chest tightness and heaviness during watching the television. He is definitely diagnosed as acute ST segment elevation MI of infero-lateral wall based on the history of the acute chest discomfort, the elevation of ST segment on ECG and increased cardiac enzymes. The immediate cardiac catheterization demonstrates the white thrombus completely occluding the LAD and the LCX. He completely recovers from acute MI after the immediate treatment with the percutaneous coronary intervention (PCI) with simultaneous thrombolytic therapy. The established risk factors for CAD cannot be identified in our case except for the low HDL while the attributing factors such as high platelet count after splenectomy, high serum ferritin and low serum testosterone are proposed.

Key words: Myocardial Infarction, Beta thalassemia/hemoglobin E, Hemosiderosis, Low HDL, Hypogonadism

บทคัดย่อ: กล้ามเนื้อหัวใจตายเฉียบพลันแบบ ST-segment ยกตัวในผู้ป่วยโรค Beta Thalassemia / Hemoglobin E สมชาย อินทศิริพงษ์, พ.บ.*, บัญชา สุขอนันต์ชัย, พ.บ.**

*หน่วยโลหิตวิทยา กลุ่มงานอายุรกรรม โรงพยาบาลมหาราชนครราชสีมา, จ.นครราชสีมา 30000

**หน่วยหทัยวิทยา กลุ่มงานอายุรกรรม โรงพยาบาลมหาราชนครราชสีมา, จ.นครราชสีมา 30000

เวชสารโรงพยาบาลมหาราชนครราชสีมา 2555; 36: 187-92.

*Hematology Unit Department of Medicine Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima 30000

**Cardiology Unit Department of Medicine Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima 30000

ภาวะกล้ามเนื้อหัวใจตายเฉียบพลันพบได้น้อยมากในผู้ป่วย beta thalassemia และไม่เคยพบเลยในผู้ป่วย beta-thalassemia/hemoglobin E เราจึงเสนอรายงานผู้ป่วย 1 รายซึ่งเป็นชายไทยอายุ 38 ปีที่มีโรคประจำตัวคือโรค beta-thalassemia/Hb E ซึ่งยืนยันการวินิจฉัยด้วยวิธี PCR ต้องได้รับเลือดประจำโรคประจำตัวอื่นได้แก่ LDL ต่ำ, HDL ต่ำ, ภาวะเหล็กเกินทุติยภูมิและฮอร์โมนเพศชายต่ำมีอาการจุกแน่นอกกะทันหันระหว่างนั่งดูโทรทัศน์ผู้ป่วยได้รับการวินิจฉัยว่าเป็น ภาวะกล้ามเนื้อหัวใจตายเฉียบพลันที่ผนังด้านหลังและด้านข้างแบบ ST ยกตัวเพราะมีอาการเจ็บแน่นอก, ตรวจคลื่นหัวใจพบการยกตัว ST segment และมีเอนไซม์ของหัวใจเพิ่มขึ้นผู้ป่วยได้รับการตรวจสวนหัวใจทันทีพบว่ามีหลอดเลือดตันเต็มของเส้นเลือด LAD และ LCX ด้วยก้อนลิ่มเลือดสีขาวแต่ผู้ป่วยฟื้นตัวเป็นปกติทันทีที่ทำการทำ percutaneous coronary intervention (PCI) ร่วมกับการให้ยาละลายลิ่มเลือดปัจจัยเสี่ยงที่ชัดเจนในผู้ป่วยรายนี้ไม่มี มีก็เพียงภาวะ HDL ต่ำร่วมกับปัจจัยเสริมอื่นๆ ได้แก่เกลือเลือดเพิ่มสูงหลังตัดม้ามภาวะเหล็กเกินและฮอร์โมนเพศชายต่ำ

คำสำคัญ: ภาวะกล้ามเนื้อหัวใจตายเฉียบพลัน, beta thalassemia/hemoglobin E, ภาวะเหล็กเกิน, ไขมันดีในเลือดต่ำ, ฮอร์โมนเพศชายต่ำ

Introduction

Beta-thalassemia / hemoglobin (Hb) E is a common genetic disease in Thailand⁽¹⁾. And its clinical characteristics mainly include anemia with varied severity from asymptomatic to transfusion-dependent, jaundice, hepato-splenomegaly⁽²⁾ and various cardiac manifestations which may be congestive heart failure, acute pericarditis or pericardial thickening with or without effusion, leaflet thickening, endocardial calcification, aortic or mitral regurgitation, pulmonary hypertension and high cardiac output in thalassemia intermedia⁽³⁾, left ventricular dysfunction⁽⁴⁾ and cardiac failure mainly attributed by the iron overload and cardiogenic death, the major cause of death, in thalassemia major^(5,6). Some experts claim that heart disease in beta thalassemia is mainly cardiomyopathy characterized by 2 types: a dilated type, with left ventricular dilatation and impaired contractility and a restrictive type, with restrictive left ventricular filling, pulmonary hypertension and right side failure. And its pathophysiology is multifactorial, mainly the myocardial iron overload and the immunoinflammation⁽⁷⁾.

Myocardial infarction (MI) has not been mentioned as the cardiac manifestation in thalassemias due to the proposed hypothesis that they are protected by the reduced blood viscosity from anemia, the hypolipidemia and the microcytosis of RBC⁽⁸⁻¹⁰⁾. Until the first case of acute ST elevation MI (STEMI) in beta-thalassemia major was reported from the USA in 2004. Her diagnosis depended on the chest pain, increased cardiac enzymes and ST elevation, but no coronary artery occlusion⁽¹¹⁾. Then, one case of acute STEMI in beta thalassemia intermedia was reported in 2009 from Lebanon whose 2 plaques were demonstrated⁽¹²⁾. Herein we report a case of acute STEMI in beta-thalassemia / Hb E, of whom the occlusion of coronary arteries is documented.

Case Report

A 38-year-old Thai man suddenly felt chest tightness and heaviness during watching the television for 3 hours. The symptom originated from the precordium and radiated to the left shoulder and is not relieved by the peptic ulcer disease regimen. He also had dyspnea

and sweating but no orthopnea, palpitation, fever or cough. The symptom was not aggravated by exertion. He denied hypertension, diabetes, smoking, drinking or family history of coronary artery disease (CAD). Since childhood, he was diagnosed as beta-thalassemia / Hb E based on the thalassemicfacy, pallor, mild jaundice, hepatosplenomegaly, Hb typing: Hb F 10.6%, Hb E 70.6% and positive β thalassemia, IVS1#5, no alpha-thalassemia-1 genes (SEA and Thai types). Blood tests: Hb 5.3 g%, WBC 13,350/mm³, NRBC 20/100 WBC, platelet 584,000/mm³, MCV 63.0 fL, MCH 18.6 pg, RDW 30.4 % and he was monthly transfused with RBC to keep Hb close to 7 g%. His spleen was cut at the age of 7 years due to too frequent transfusion. Hypogonadism was additionally diagnosed at the age of 32 years because of the delayed secondary sex characteristics and the testosterone of <0.10-0.11 ng/mL (Normal 3.0-10.6). Other tests: ferritin 2,040 ng/mL, serum iron 61.0 mcg%, transferrin 213 mcg%, erythropoietin 82.7 mU/mL (Normal 2.6-34.0), triglyceride 129 mg%, LDL 61 mg%, HDL 18 mg%, fibrinogen 72 mg%, homocysteine 9.5 micromole/L (Normal 5.9-15.3), protein S 85.2%, protein C 71.8%, antithrombin III 88.4%, normal kidney, liver function tests and coagulogram, factor VIII activity 234%. HBsAg, anti-HCV and anti-HIV were negative. He was regularly treated with sublingual methyl testosterone and deferiprone.

On admission, BP 107/70 mmHg, PR 105/min, BW 37 Kg, Height 1.55 m, BMI 15.4 kg/m², he had thalassemicfacy with generalized hyperpigmentation, moderate pallor, mild jaundice, heart apex at the 6th intercostal space, MCL, hepatomegaly 3 FB and no leg edema.

Blood tests: Hb 8.6 g%, WBC 33,000/mm³, NRBC 77/100 WBC, platelet 512,000/mm³, FBS 100 mg%, Hb A1c 4.4%, creatinine 1.3 mg%, direct bili-rubin 1.7 mg%, total bilirubin 6.0 mg%, AST 61, ALT 57, AP 64 U/L, albumin 4.3 g%, ferritin 1,465.5 ng/mL, CK-MB mass 3.8 ng/mL (Normal 0-3), troponin-I 0.13 ng/mL (Normal 0-0.1).

The ECG showed the ST elevation at leads II, III, aVF, V₅-V₆ and ST depression in V₁-V₃. Chest film showed cardiomegaly. The immediate percutaneous cardiac catheterization revealed the complete occlusion of the distal LAD and distal LCX due to the white thrombi. The thrombus was aspirated from LAD for the pathological analysis.

He was diagnosed as acute STEMI of the infero-lateral wall in a case of beta-thalassemia / Hb E. Other morbidities were hemosiderosis and hypogonadism. He was treated with percutaneous coronary intervention with stenting and streptokinase, heparin, eptifibatide, clopidogrel and aspirin. The TIMI flow completely recovered and all elevated ST segments became normal. The ejection fraction is normal. He was discharged home in a few days with aspirin, clopidogrel, simvastatin, folic acid and ranitidine.

Discussion

Our case is definitely diagnosed as acute STEMI based on the combination of the acute chest symptom, increased cardiac enzyme and the ST elevation in infero-lateral wall on ECG⁽¹³⁾ and confirmed to have coronary artery occlusion with the cardiac catheterization.

Among established risk factors for CAD such as smoking, dyslipidemia, DM, hypertension, abdominal obesity, or family history⁽¹⁴⁻¹⁵⁾, the only one our patient has, is dyslipidemia. Before the heart attack, he has low LDL and low HDL, the common findings in beta-thalassemia / Hb E⁽¹⁶⁾. In fact, high LDL ($> 95 \text{ mg\%}$)⁽¹⁷⁾ or low HDL ($< 40 \text{ mg\%}$)⁽¹⁸⁾ or low HDL with low LDL⁽¹⁹⁾ is well known as the risk factor for CAD.

Severe thalassemia has thrombophilia particularly after splenectomy, i.e., platelet activation, enhanced RBC adherence to endothelium, reduced protein C⁽¹²⁰⁾ and S, increased thrombin generation⁽²¹⁾, platelets or beta-thromboglobulin⁽²²⁾ but the thromboses have been rarely recognized, such as cerebral venous thrombosis in beta-thalassemia/Hb E^(23,24), venous thromboembolism⁽²⁵⁾, portal vein thrombosis in thalassemia major or intermedia⁽²⁶⁾, pulmonary hypertension in splenectomized beta thalassemia⁽²⁷⁾. Whereas AMI in beta thalassemia major^(11,12) are rare, MI in beta-thalassemia / Hb E has never been reported.

When patients have been transfused with 75 units of blood or more, it can lead to markedly increased serum ferritin, and 50% of recipients can accumulate the excess iron in myocardium⁽²⁸⁾. But the higher serum ferritin is not associated with the extent of coronary atherosclerosis⁽²⁹⁾, so far MI is still rare in thalassemia major, and their major cause of death is cardiomyopathy, not AMI. Our case has high serum ferritin from transfusions, hemochromatosis of the myocardium should have been expected but his ejection fraction is still normal.

Thrombophilia after splenectomy especially thrombocytosis (platelet $> 500,000/\text{mm}^3$) can be the cause of AMI^(30,31), two cases of MI after splenectomy occurred within 8-12 days. Although our

case has persistent thrombocytosis (platelet $512,000-593,000/\text{mm}^3$) but the splenectomy was performed since his seven years of age.

The risk of MI in our case may be attributed by the male hypogonadism (testosterone $< 0.1 \text{ ng/mL}$) because hypogonadism increases risk of death in cardio-vascular disease⁽³²⁾, furthermore the low serum dehydro-epiandrosterone can predict death from all causes and from ischemic heart disease in older men⁽³³⁾.

In conclusion, the acute MI can happen in the patient with beta-thalassemia / Hb E because of low HDL, one of modifiable risk factors, as well as other factors that may possibly attribute risks of MI, including secondary hemochromatosis, thrombophilia after splenectomy and hypogonadism, the common complications in cases of severe thalassemia.

References:

1. Fucharoen S, Winichagoon P. Haemoglobinopathies in South East Asia. *Indian J Med Res* 2011; 134: 498-506.
2. Olivieri NF, Pakbaz Z, Vichinsky E. Hb E/ beta-thalassaemia: a common & clinically diverse disorder. *Indian J Med Res* 2011; 134: 522-31.
3. Aessopos A, Farmakis D, Karagiorga M, Vorkaridou E, Loutradi A, Hatziliami A, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. *Blood* 2001; 97: 3411-6.
4. Ehlers KH, Levin AR, Markenson AL, Markus JR, Klein AA, Hilgartner MW, et al. Longitudinal study of cardiac function in thalassemia major. *Ann N Y Acad Sci* 1980; 344: 397-404.
5. Zurlo MG, De Stefano P, Borgna-Pignatti C. Survival and causes of death in thalassaemia major. *Lancet* 1989; 2: 27-30.
6. Aessopos A, Kati M, Tsironi M. Congestive heart failure and treatment in thalassemia major. *Hemoglobin* 2008; 32: 63-73.

7. Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, et al. . Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. *Circ Heart Fail* 2010; 3: 451-8.
8. Gallerani M, Scapoli C, Cicognani I, Ricci A, Martinelli L, Cappato R, et al. Thalassemia trait and MI low infarction incidence in male subjects confirmed. *J Intern Med* 1991; 230: 109-11.
9. Tassiopoulos T, Stamatelos G, Zakopoulos N, Fessas P, Eliopoulos GD. Low incidence of acute myocardial infarction in beta-thalassemia trait carriers. *Haematologia (Budapest)* 1995; 26: 199-203.
10. Wang CH, Schilling R. Myocardial infarction and thalassemia trait: an example of heterozygote advantage. *Am J Hematol* 1995; 49: 73-5.
11. Fridlender ZG, Rund D. Myocardial infarction in a patient with beta-thalassemia major: First report. *Am J Hematol* 2004; 75: 52-5.
12. El Rassi FA, Ismaeel HA, Koussa SC, Taher AT. Myocardial infarction in a 28-year-old thalassemia intermedia patient. *Clin Appl Thromb Hemost* 2009; 15: 467-9.
13. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. *Circulation* 2012; 126: 2020-35.
14. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004; 364: 937-52.
15. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. *Eur Heart J* 2008; 29: 932-40.
16. Insiripong S, Yingsitsiri W, Boondumrongsakul J. Lipid profile in the patients with beta thalassemia/hemoglobin E. *Bull Department Medical Services* 2012; 37: 129-33.
17. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-1, and B, and HDL-density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2001; 104: 1108-13.
18. Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. *Am Heart J* 1983; 106 (5 Pt 2): 1191-200.
19. Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. *Circulation* 2002; 105: 1424-8.
20. Hergüner Mö, Incecik F, Altunbasak S, Sağmaz I, Leblebisatan G. Recurrent cerebral stroke in a thalassemic patient. *Hematol Oncol Stem Cell Ther* 2008; 1: 136-8.
21. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. *Blood* 2009; 114: 2861-8.
22. Setiabudy R, Wahidiat PA, Setiawan L. Platelet aggregation and activation in thalassemia major patients in Indonesia. *Clin Appl Thromb Hemost* 2008; 14: 346-51.
23. Wong V, Yu YL, Liang RH, Tso WK, Li AM, Chan TK. Cerebral thrombosis in beta-thalassemia / hemoglobin E disease. *Stroke* 1990; 21: 812-6.
24. Ho ACH, Li AM, Chik KW, Shing MK, Li CK. Headache in a patient with beta-thalassemia intermedia. *HK J Paediatr (new series)* 2006; 11: 64-8.
25. Borgna-Pignatti C, Carnelli V, Caruso V, Dore F,

- De Mattia D, DiPalma A, et al. Thromboembolic events in beta thalassemia major: An Italian multicenter study. *ActaHaematol* 1998; 99: 76-9.
26. Canatan D, Zorlu M, Bayir N, Ertürk C, Dorak A, Oğuzl N, et al. Thrombosis after splenectomy in patients with thalassemia. *Turk J Haematol* 2001; 18: 259-63.
 27. Elmoneim AA, El-Said A, Elmoneim ESA. Thrombocytosis in splenectomized β -thalassemia children and its association with pulmonary hypertension. *J ApplSci Res* 2012; 8: 4058-63.
 28. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferoxamine: indication of close relation between myocardial iron content and chelatable iron pool. *Blood* 2003; 101: 4632-9.
 29. Auer J, Rammer M, Berent R, Weber T, Lassnig E, Eber B. Body iron stores and coronary atherosclerosis assessed by coronary angiography. *NutrMetab Cardiovasc Dis* 2002; 12: 285-90.
 30. Khan PN, Nair RJ, Olivares J, Tingle LE, Li Z. Postsplenectomy reactive thrombocytosis. *Proc (BaylUniv Med Cent)* 2009; 22: 9-12.
 31. Ghaffari S, Pourafkari L. Acute myocardial infarction in a patient with post-splenectomy thrombocytosis: A case report and review of literature. *Cardiol J* 2010; 17: 79-82.
 32. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. *J Clin Endocrinol Metab* 2008; 93: 68-75.
 33. Ohlsson C, Labrie F, Barrett-Connor E, Karlsson MK, Ljunggren O, Vandenput L, et al. Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men. *J Clin EndocrinolMetab* 2010; 95: 4406-14.